Phase 3b, interventional, adaptive clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every two weeks as monotherapy compared to placebo in subjects with moderate to severe atopic hand eczema who are candidates

CLINICAL TRIAL WITH MEDICINES